Data for: A phase II, multicenter, single-arm trial of eribulin as first-line therapy for aggressive taxane-pretreated HER2-negative metastatic breast cancer patients: The MERIBEL study

Name: Data for: A phase II, multicenter, single-arm trial of eribulin as first-line therapy for aggressive taxane-pretreated HER2-negative metastatic breast cancer patients: The MERIBEL study
Creator: Antonio Llombart
Published: 2019-01-09T15:07:18.323Z
Keywords: Oncologist, Publication

Llombart, Antonio; Antón, Antonio; Garau, Isabel; García, Mirta; Illarramendi, José Juan; Rodriguez, Cesar; Afonso, Noemia; Aguirre, Elena; Zamora, Pilar; Sampayo, Miguel; Ortega, Vanesa; Blanco, Esperanza; Martínez-García, María; Cortes, Javier; Calvo, Lourdes; Perez Garcia, Jose; Fernández, Yolanda

doi:10.17632/ffg8fv5ph5.1

Data for: A phase II, multicenter, single-arm trial of eribulin as first-line therapy for aggressive taxane-pretreated HER2-negative metastatic breast cancer patients: The MERIBEL study

Published: 9 January 2019| Version 1 | DOI: 10.17632/ffg8fv5ph5.1

Contributors:

Antonio Llombart, Antonio Antón, Isabel Garau, Mirta García, José Juan Illarramendi, Cesar Rodriguez, Noemia Afonso, Elena Aguirre, Pilar Zamora, Miguel Sampayo, Vanesa Ortega, Esperanza Blanco, María Martínez-García, Javier Cortes, Lourdes Calvo, Jose Perez Garcia, Yolanda Fernández

Description

A phase II, multicenter, single-arm trial of eribulin as first-line therapy for aggressive taxane-pretreated HER2-negative metastatic breast cancer patients: The MERIBEL study

Data for: A phase II, multicenter, single-arm trial of eribulin as first-line therapy for aggressive taxane-pretreated HER2-negative metastatic breast cancer patients: The MERIBEL study

Description

Files

Categories

Licence